<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800085</url>
  </required_header>
  <id_info>
    <org_study_id>KD_BF_01</org_study_id>
    <nct_id>NCT00800085</nct_id>
  </id_info>
  <brief_title>Beta Cell Function in (Pre) Type 1 Diabetes</brief_title>
  <official_title>Beta Cell Function in (Pre) Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ-VUB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ-VUB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will establish criteria indicating short-term loss of beta cell mass and therefore
      accelerated progression towards type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will establish criteria indicating short-term loss of beta cell mass and therefore
      accelerated progression towards type 1 diabetes. These criteria may help to determine the
      time point and type of prevention may contribute to the composition of homogeneous groups of
      study subjects (based on residual beta cell mass, homogeneous risk of beta cell destruction
      during intervention) and may lead to the identification of functional markers that could be
      used as surrogate endpoints. This may reduce the number of subjects needed to treat as well
      as the follow-up time necessary to study significant effects of the test substance.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The systematic and simultaneous determination of markers of functional beta cell mass and immune status allows stratification according to the stage of the pathogenic process rather than according to a late metabolic consequence of this process</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>FDR of type 1 diabetes patients receiving glucose 20%</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>First Degree Relatives of diabetes type 1 patient with a high, intermedian or low risk (accoring to the criteria of the protocol), for developing diabetes type 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucose 20%</intervention_name>
    <description>maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals</description>
    <arm_group_label>FDR of type 1 diabetes patients receiving glucose 20%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The following groups of first degree relatives of type1 diabetes patients with normal
             glucose tolerance during OGTT (5-39 years) will be included after informed consent on
             the basis of their antibody status (n = 40 per group):

               -  IA-2A-positives;

               -  Ab.-positives (positive for at least 2 different Abs. (IAA, GADA and/or ICA)
                  and/or persistently Ab.-positive for 1 of these Abs;

               -  persistently Ab.-negatives.

          -  40 type 1 diabetes patients with the following criteria will be studied: 1) aged 12-39
             years; 2) &lt; 4 weeks of insulin treatment; 3) auto-Ab.-positive; 4) polyuria since &lt; 6
             months; 5) &lt; 10% weight loss over the last 6 months; 6) informed consent.

        Exclusion Criteria:

          -  Pregnancy or lactation in women

          -  Use of illicit drugs or overconsumption of alcohol (&gt; 3 beers/day) or history of drug
             or alcohol abuse

          -  Being legally incapacitated, having significant emotional problems at the time of the
             study, or having a history of psychiatric disorders

          -  Having received antidepressant medications during the last 6 months

          -  Treatment with immune modulating or diabetogenic medication (such as corticosteroids)

          -  Presently participating in another clinical study

          -  History of any illness that, in the opinion of the investigator, might confound the
             results of the study or pose additional risks to the subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>katelijn Decochez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Brussels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214-23.</citation>
    <PMID>382871</PMID>
  </reference>
  <reference>
    <citation>Gorus FK, Goubert P, Semakula C, Vandewalle CL, De Schepper J, Scheen A, Christie MR, Pipeleers DG. IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. The Belgian Diabetes Registry. Diabetologia. 1997 Jan;40(1):95-9.</citation>
    <PMID>9028724</PMID>
  </reference>
  <reference>
    <citation>Decochez K, De Leeuw IH, Keymeulen B, Mathieu C, Rottiers R, Weets I, Vandemeulebroucke E, Truyen I, Kaufman L, Schuit FC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. IA-2 autoantibodies predict impending type I diabetes in siblings of patients. Diabetologia. 2002 Dec;45(12):1658-66. Epub 2002 Nov 12.</citation>
    <PMID>12488955</PMID>
  </reference>
  <reference>
    <citation>Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, Bonifacio E, Ziegler AG. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004 Feb;53(2):384-92. Erratum in: Diabetes. 2004 Apr;53(4):1175-6.</citation>
    <PMID>14747289</PMID>
  </reference>
  <reference>
    <citation>Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia. 2006 May;49(5):881-90. Epub 2006 Mar 3.</citation>
    <PMID>16514546</PMID>
  </reference>
  <reference>
    <citation>Maclaren N, Lan M, Coutant R, Schatz D, Silverstein J, Muir A, Clare-Salzer M, She JX, Malone J, Crockett S, Schwartz S, Quattrin T, DeSilva M, Vander Vegt P, Notkins A, Krischer J. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives. J Autoimmun. 1999 Jun;12(4):279-87.</citation>
    <PMID>10330299</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2008</study_first_submitted>
  <study_first_submitted_qc>November 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <last_update_submitted>December 27, 2013</last_update_submitted>
  <last_update_submitted_qc>December 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ-VUB</investigator_affiliation>
    <investigator_full_name>Bart Keymeulen</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>first degree relatives of type 1 diabetes patients</keyword>
  <keyword>hyperglycemic clamp test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

